Clinical Trial Update: Testing the Combination of Copanlisib, Nivolumab and Ipilimumab in Patients With Advanced Cancer and Lymphoma [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial is evaluating the three-drug combination of Copanlisib, Nivolumab, and Ipilimumab in patients with advanced cancer and lymphoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lymphoma
• Malignant Solid Tumor
• Unresectable Malignant Solid Tumor

Drugs mentioned

• Aliqopa (copanlisib)
• OPDIVO (nivolumab)
• Yervoy (ipilimumab)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Lymphoma, Metastatic Malignant Solid Neoplasm | Phase 1 | Status: ACTIVE_NOT_RECRUITING